PharmaFocus Today – Page 100 – media

J&J expands dermatology portfolio with $850m Proteologix acquisition

In a bid to solidify its footing in dermatology, Johnson & Johnson (J&J) has announced that it will purchase the immune-mediated disease-focused biotech Proteologix in a $850m cash buyout, with the potential for additional milestone payments. The host of bispecific antibodies brought by Proteologix to the deal will add depth to J&J’s immunology pipeline, and more specifically, bolster its position to address atopic dermatitis (AD). Among Proteologix’s assets is PX128, a bispecific antibody designed to target interleukin (IL)-13, as well as the cytokine TSLP, which is being developed for the treatment of patients with moderate to severe AD and moderate to severe asthma. The acquisition also covers the preclinical stage candidate, PX130, a bispecific antibody designed to target both IL-13 and IL-22 to inhibit inflammation, restore the skin barrier, and prevent environmental trigger-mediated inflammation of the skin. The asset is under development for the treatment of moderate to severe AD. ...
- Source: drugdu
- 83
- May 21, 2024
CanSinoBio’s Yu Xuefeng was invited to attend the Asia Healthcare Summit Forum

On May 16, the 4th Asia Healthcare Summit (ASGH), jointly organized by the Hong Kong SAR Government and the Hong Kong Trade Development Council, was held at the Hong Kong Convention and Exhibition Centre. Under the theme of “Innovation – Inclusion – Effectiveness”, the forum covered topics such as challenges and opportunities in the global healthcare industry, the latest developments in medical technology and business opportunities in the Asian healthcare industry, aiming to bring together elites in the global healthcare field to explore ways of innovation and development. Dr. Xuefeng Yu, Chairman and CEO of CanSinoBio, was invited to attend the event to discuss the prospects and business opportunities of the Asian healthcare industry with policy makers, healthcare experts, scholars, business leaders and investors from all over the world, and to strengthen the communication and cooperation among global healthcare industry participants. At the conference, Academician Cao Xuetao, Deputy Director of ...
- Source: drugdu
- 80
- May 21, 2024
Study finds link between malaria parasites developing antimalarial drug resistance

Spread through Anopheles mosquitoes, the disease affected around 249 million people globally in 2022 Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), in collaboration with the Massachusetts Institute of Technology, Columbia University Irving Medical Center and Nanyang Technological University (NTU), Singapore, have identified a link between malaria parasites developing resistance to antimalarial drugs. Affecting around 249 million people globally in 2022, malaria is a mosquito-borne disease that occurs when parasites spread to humans through the bites of infected Anopheles mosquitoes. Specifically focusing on an antimalarial drug known as artemisinin (ART), researchers used a cellular process called transfer ribonucleic acid (tRNA) modification – a mechanism which allows cells to respond rapidly to stress by altering RNA molecules within a cell. ART-based combination therapies are a first-line treatment for patients with uncomplicated malaria and help reduce the number of parasites during the ...
- Source: drugdu
- 75
- May 21, 2024
Liverpool and McMaster University announce £300,000 strategic research partnership

Areas include health research across life stages, from paediatrics to health ageing and resilience The University of Liverpool and McMaster University have announced an institutional strategic partnership, offering £300,000 in seed funding to nine selected projects to support the development of collaborations in key areas of research. The areas of research include health research across life stages, from paediatrics to healthy ageing and resilience, along with social sciences, humanities and research, as well as development in port-related activities. The projects selected were announced by McMaster at a celebratory event with representatives from the University of Liverpool in attendance. The three health research projects selected focus on innovative antibiotic discovery to combat invasive Salmonella in Africa, engineering perfusable vascular organoids for ageing and chronic disease studies and developing pharmacogenetic polygenic risk scores using machine learning methods. David Farrar, president, McMaster, commented: “We’re proud to partner with the University of Liverpool to ...
- Source: drugdu
- 77
- May 21, 2024
Virginia Medicaid Taps Aeroflow Health for Lactation Services

Aeroflow Health, a health tech company, has expanded its lactation consultation services to Virginia Medicaid, it announced Thursday. Asheville, North Carolina-based Aeroflow Health was founded in 2001 and offers an array of medical devices covered by insurance. The company has four lines: Aeroflow Breastpumps, Aeroflow Diabetes, Aeroflow Sleep and Aeroflow Urology. In addition to medical devices, it provides education and consultations. The company has partnerships with more than 1,000 insurance plans. Through Aeroflow’s partnership with Virginia Medicaid and its managed care organizations, new mothers can access breast pumps from Aeroflow. They will also be connected to Aeroflow’s network of lactation consultants. Members can receive one-on-one lactation consultations and online courses that cover topics like breastfeeding, pumping and storing breastmilk. “This partnership between Aeroflow Health and Virginia Medicaid broadens access to lactation services from Aeroflow Breastpumps for new and expecting mothers,” Amanda Minimi, director of corporate development at Aeroflow Health, told ...
- Source: drugdu
- 125
- May 20, 2024
Weak brain circuit connection found to influence overeating and obesity

Why can some people easily stop eating when they are full and others can’t, which can lead to obesity? A Northwestern Medicine study has found one reason may be a newly discovered structural connection between two regions in the brain that appears to be involved in regulating feeding behavior. These regions involve the sense of smell and behavior motivation. The weaker the connection between these two brain regions, the higher a person’s Body Mass Index (BMI), the Northwestern scientists report. The investigators discovered this connection between the olfactory tubercle, an olfactory cortical region, which is part of the brain’s reward system, and a midbrain region called the periaqueductal gray (PAG), involved in motivated behavior in response to negative feelings like pain and threat and potentially in suppression of eating. The study will be published May 16 in the Journal of Neuroscience. Previous research at Northwestern by co-author Thorsten Kahnt, now ...
- Source: drugdu
- 112
- May 20, 2024
EmpiRx Announces New AI-Powered Platform as Part of Push to Change PBMs

Mike Hollan The platform will use AI technology to provide pharmacists with more tools. The relationship between the pharma industry, pharmacists, and customers continues to evolve. EmpiRx Health, a PBM company headquartered in NJ, announced that it is launching a new AI-powered platform.1 The new platform is called Clinically, and it will use AI technology to help pharmacists with claims adjudication, clinical reviews, and other features that EmpiRx says will put the pharmacists at the center of the PBM model. In a press release, EmpiRx’s CEO Danny Sanchez said, “Our new Clinically platform clearly demonstrates EmpiRx Health’s strong commitment to transforming the pharmacy care industry by creating the PBM of the future – one that’s already providing the highest quality service to customers, patients, and advisor partners. This PBM revolution was long overdue. Far from helping plan sponsors to manage and lower drug costs, the traditional PBM model, which prioritizes ...
- Source: drugdu
- 95
- May 20, 2024
The View from Investors

Mike Hollan Industry experts gather to discuss the current investor market and how the IRA may impact the industry in the coming years. Financial Times US Pharma and Biotech Summit 2024After the post-Covid crash, investors are seeing promising trends in the pharma and biotech industry in 2024. The following speakers presented a panel discussing the industry from an investors perspective at the Financial Times’ US Pharma and Biotech Summit 2024 in New York City: Harmeet Dhillon, head of public policy at GSK; Amit Sinha, chief investment officer at Goldman Sachs; Darius Lakdawalla, quintiles chair in pharmaceutical development at the University of Southern California; and Johanna Grossman, head of healthcare and US life sciences at the US Stock Exchange. Oliver Barnes, a US pharmaceutical and biotech correspondent for the Financial Times moderated the event. The conversation focused on both the current state of the industry and where each of the speakers ...
- Source: drugdu
- 131
- May 20, 2024
USFDA concludes inspection of Indoco’s Rabale facility

Indoco Remedies announced that the United States Food and Drug Administration (USFDA) successfully completed inspection of its API Kilo Lab manufacturing facility at Rabale, Navi Mumbai and Indoco Analytical Solutions (IAS) division. The inspection concluded with zero Form 483 observations. “We remain committed to ensuring the safety and efficacy of our products while maintaining the trust of our customers and stakeholders”, said Aditi Panandikar, MD, Indoco Remedies. https://www.expresspharma.in/usfda-concludes-inspection-of-indocos-rabale-facility/
- Source: drugdu
- 101
- May 20, 2024
Zydus, MSN partner to license and supply Cabozantinib Tablets for the US

Zydus Lifesciences announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX) for the US market. As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the product in the US market. MSN was the first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX. The total addressable market opportunity of Cabozantinib Tablets in the US is approximately $ 1,464 million. https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-ipsen-enter-exclusive-licensing-agreement
- Source: drugdu
- 125
- May 20, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.